Back to Pediatrics
Pediatricsv2017_ahaEvidence-Based

Kawasaki Disease Diagnostic Criteria

Diagnoses Kawasaki Disease using fever duration and principal clinical features. Kawasaki disease is a systemic vasculitis of childhood that can cause coronary artery aneurysms if untreated. Diagnosis requires fever ≥4 days plus ≥4 of 5 principal clinical features, or fever ≥5 days plus 2-3 features (incomplete Kawasaki).

Clinical Input Parameters

days
Range: 1 — 30 days
Clinical Assessment
Awaiting Parameters
diagnosis
—category
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Kawasaki Disease Diagnostic Criteria is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within pediatrics.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Classic KD: Fever ≥4 days + ≥4 of 5 principal features. Incomplete KD: Fever ≥5 days + 2-3 principal features with supportive laboratory findings or coronary abnormalities

Clinical Pearls & Practice Notes

  • Classic Kawasaki disease: fever ≥4 days plus ≥4 of 5 principal clinical features
  • Incomplete Kawasaki disease: fever ≥5 days plus 2-3 principal features (more common in infants <6 months)
  • Principal features may not appear simultaneously and can resolve before diagnosis
  • Early diagnosis and treatment (within 10 days of fever onset) reduces risk of coronary artery abnormalities
  • Infants ≤6 months are at highest risk for incomplete presentation and coronary complications
  • IVIG (intravenous immunoglobulin) plus aspirin is first-line treatment
  • Follow-up echocardiography is essential to monitor for coronary artery changes
  • Second-line treatments for IVIG-resistant cases include infliximab, corticosteroids, or cyclosporine

Evidence & Literature Citations

  1. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association. Circulation. 2017;135(17):e927-e999.
  2. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2004;110(17):2747-71.
  3. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47(2):232-4.
  4. Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010;125(2):e234-41.

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.